相关实验视频

Updated: Jul 6, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

普拉米佩克索尔可以预防糖尿病神经病变:对氧化应激,TLR4/IRAK-1/TRAF-6/NF-κB和下游炎症媒介的作用

Nada H Eisa¹, Sahar A Helmy¹, Dalia H El-Kashef²

¹Biochemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.

International immunopharmacology

|January 10, 2024

概括

普拉米醇 (PPX) 通过减少神经损伤和炎症,对糖尿病神经病变 (DN) 产生神经保护作用. 这项研究表明,PPX可能是减缓糖尿病患者DN进展的潜在治疗方法.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
糖尿病学糖尿病学

背景情况:

糖尿病神经病变 (DN) 是糖尿病的严重并发症,导致神经损伤,疼痛和感觉丧失.
目前对DN的治疗方法不足,这凸显了对新型治疗方法的需求.
作为多巴胺激动剂的pramipexole (PPX) 正在研究其在DN中的潜在神经保护性质.

研究的目的:

在糖尿病神经病变 (DN) 的实验模型中研究普拉米佩克索尔 (PPX) 的神经保护作用.
评估PPX对坐骨神经组织学,氧化应激和DNA炎症通路的影响.

主要方法:

斯普雷格·道利 (Sprague Dawley) 鼠被分为五个组,包括对照组和与不同剂量的PPX治疗的链毒素 (STZ) 诱导的DNA模型.
通过坐骨神经组织病理学,氧化应激标志物和TLR4/MyD88/IRAK-1/TRAF-6/NF-κB信号通路的蛋白质表达来评估神经保护.

主要成果:

在DN大鼠中,PPX治疗显著改善了神经炎症和亡的组织病理征兆.
施用PPX可降低坐骨神经中的氧化应激.
PPX降低了关键炎症调解者的表达,包括TLR4,MyD88,IRAK-1,TRAF-6,NF-κB,TNF-α,IL-1β和ICAM-1.

结论:

普拉米醇 (PPX) 在糖尿病神经病变 (DN) 的大鼠模型中显示出显著的神经保护作用.
PPX的益处与TLR4/MyD88/IRAK-1/TRAF-6/NF-κB信号通路的调节有关.
这些发现表明PPX具有作为缓解DN进展的治疗剂的潜力.

关键词:

糖尿病神经病变糖尿病神经病变药物重新定位药物重新定位普拉米佩克索尔 (pramipexole) 是一种药物.保护性治疗是一种保护性治疗.这是一个TLR-4的特点.

更多相关视频

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise

Published on: July 14, 2023

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

相关概念视频

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...